Erin M Rock1, Cheryl L Limebeer1, Gavin N Petrie1, Lauren A Williams1, Raphael Mechoulam2, Linda A Parker3. 1. Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, Ontario, N1G 2W1, Canada. 2. Institute of Drug Research, School of Pharmacy Medical Faculty, Hebrew University of Jerusalem, Jerusalem, Israel. 3. Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, Ontario, N1G 2W1, Canada. parkerl@uoguelph.ca.
Abstract
RATIONALE: Cannabis is commonly used by humans to relieve stress. OBJECTIVES AND METHODS: Here, we evaluate the potential of intraperitoneally (i.p.) administered Δ9-tetrahydrocannabiol (THC) and cannabidiolic acid (CBDA, the precursor of cannabidiol [CBD]) to produce dose-dependent effects on anxiety-like responding in the light-dark (LD) emergence test of anxiety-like responding in rats, when administered acutely or chronically (21 days). As well, we evaluate the potential of THC, CBDA, and CBD to reduce anxiogenic responding produced by foot shock (FS) stress 24 h prior to the LD test. RESULTS: In the absence of the explicit FS stressor, THC (1 and 10 mg/kg) produced anxiogenic-like responding when administered acutely or chronically, but CBDA produced neither anxiogenic- nor anxiolytic-like responding. Administration of FS stress 24 h prior to the LD test enhanced anxiogenic-like responding (reduced time spent and increased latency to enter the light compartment) in rats pretreated with either vehicle (VEH) or THC (1 mg/kg); however, administration of CBDA (0.1-100 μg/kg) or CBD (5 mg/kg) prevented the FS-induced anxiogenic-like responding (an anxiolytic-like effect). The 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist, WAY100635, reversed CBDA's anxiolytic effect (1 μg/kg). Combining an anxiolytic dose of CBDA (1 μg/kg) or CBD (5 mg/kg) with an anxiogenic dose of THC (1 mg/kg) did not modify THC's anxiogenic effect. CONCLUSION: These results suggest the anxiolytic effects of CBDA and CBD may require the presence of a specific stressor.
RATIONALE: Cannabis is commonly used by humans to relieve stress. OBJECTIVES AND METHODS: Here, we evaluate the potential of intraperitoneally (i.p.) administered Δ9-tetrahydrocannabiol (THC) and cannabidiolic acid (CBDA, the precursor of cannabidiol [CBD]) to produce dose-dependent effects on anxiety-like responding in the light-dark (LD) emergence test of anxiety-like responding in rats, when administered acutely or chronically (21 days). As well, we evaluate the potential of THC, CBDA, and CBD to reduce anxiogenic responding produced by foot shock (FS) stress 24 h prior to the LD test. RESULTS: In the absence of the explicit FS stressor, THC (1 and 10 mg/kg) produced anxiogenic-like responding when administered acutely or chronically, but CBDA produced neither anxiogenic- nor anxiolytic-like responding. Administration of FS stress 24 h prior to the LD test enhanced anxiogenic-like responding (reduced time spent and increased latency to enter the light compartment) in rats pretreated with either vehicle (VEH) or THC (1 mg/kg); however, administration of CBDA (0.1-100 μg/kg) or CBD (5 mg/kg) prevented the FS-induced anxiogenic-like responding (an anxiolytic-like effect). The 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist, WAY100635, reversed CBDA's anxiolytic effect (1 μg/kg). Combining an anxiolytic dose of CBDA (1 μg/kg) or CBD (5 mg/kg) with an anxiogenic dose of THC (1 mg/kg) did not modify THC's anxiogenic effect. CONCLUSION: These results suggest the anxiolytic effects of CBDA and CBD may require the presence of a specific stressor.
Authors: David Schofield; Chris Tennant; Louise Nash; Louisa Degenhardt; Alison Cornish; Coletta Hobbs; Gail Brennan Journal: Aust N Z J Psychiatry Date: 2006 Jun-Jul Impact factor: 5.744
Authors: Fabrício A Moreira; Daniele C Aguiar; Francisco S Guimarães Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2006-07-31 Impact factor: 5.067
Authors: Nicole L Schramm-Sapyta; Young May Cha; Saba Chaudhry; Wilkie A Wilson; H Scott Swartzwelder; Cynthia M Kuhn Journal: Psychopharmacology (Berl) Date: 2007-01-09 Impact factor: 4.530
Authors: Alexia Polissidis; Olga Chouliara; Andreas Galanopoulos; Georgia Rentesi; Maria Dosi; Thomas Hyphantis; Marios Marselos; Zeta Papadopoulou-Daifoti; George G Nomikos; Christina Spyraki; Eleni T Tzavara; Katerina Antoniou Journal: Int J Neuropsychopharmacol Date: 2009-11-27 Impact factor: 5.176
Authors: Chandni Hindocha; Tom P Freeman; Grainne Schafer; Chelsea Gardener; Ravi K Das; Celia J A Morgan; H Valerie Curran Journal: Eur Neuropsychopharmacol Date: 2014-12-05 Impact factor: 4.600
Authors: Marieka V DeVuono; Kiri L Wills; Danielle V MacPherson; Kelly M Hrelja; Linda A Parker Journal: Psychopharmacology (Berl) Date: 2017-08-12 Impact factor: 4.530
Authors: Alyssa M Myers; Patrick B Siegele; Jeffrey D Foss; Ronald F Tuma; Sara Jane Ward Journal: Br J Pharmacol Date: 2018-03-01 Impact factor: 8.739
Authors: Kelsey G Guenther; Cassidy E Wideman; Erin M Rock; Cheryl L Limebeer; Linda A Parker Journal: Psychopharmacology (Berl) Date: 2018-09-24 Impact factor: 4.530
Authors: Roger G Pertwee; Erin M Rock; Kelsey Guenther; Cheryl L Limebeer; Lesley A Stevenson; Christeene Haj; Reem Smoum; Linda A Parker; Raphael Mechoulam Journal: Br J Pharmacol Date: 2017-12-05 Impact factor: 8.739
Authors: Marieka V DeVuono; Olivia La Caprara; Gavin N Petrie; Cheryl L Limebeer; Erin M Rock; Matthew N Hill; Linda A Parker Journal: Cannabis Cannabinoid Res Date: 2020-12-21
Authors: Cora E Smiley; Heyam K Saleh; Katherine E Nimchuk; Constanza Garcia-Keller; Justin T Gass Journal: Behav Brain Res Date: 2021-08-10 Impact factor: 3.352
Authors: Lyndsey L Anderson; Maia G Etchart; Dilara Bahceci; Taliesin A Golembiewski; Jonathon C Arnold Journal: Sci Rep Date: 2021-07-22 Impact factor: 4.379